Transcept names John Kollins SVP and CBO
This article was originally published in Scrip
Transcept Pharmaceuticals, a specialty pharmaceutical company focused on the development of products that address therapeutic needs in neuroscience, has appointed John Kollins senior vice-president and chief business officer, reporting to Glenn Oclassen, president and CEO of Transcept. Prior to joining Transcept, Mr Kollins provided strategy, business development and transaction services to life science companies via Parnassus Advisors, the consulting and advisory firm he established.
You may also be interested in...
Almirall has launched its irritable bowel syndrome drug Constella (linaclotide) in six European countries, with several other launches planned for later this year.
Dermira, a dermatology-focused biotech, has raised $35m in a series B financing.
Clovis Oncology has raised its public offering, announced 11 June, from $170m to $240m.